Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 12/20 | 1.00 |
| ▸ | FAAH | O00519 | 8/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | CNR1 | P21554 | 3/20 | 0.67 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | ATM | Q13315 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30848467 | 0.94 | CNR2 (0.89) | CNR2FAAHMEN1KMT2ACNR1 | |
| SCHEMBL2637643 | 0.87 | CNR2 (0.76) | CNR2FAAHMEN1KMT2ACNR1 | |
| SCHEMBL6084569 | 0.80 | P2RX7 (1.00) | CNR2FAAHMEN1KMT2AP2RX7 | |
| SCHEMBL15121240 | 0.79 | TSHR (1.00) | CNR2FAAHCNR1KDM4EALDH1A1 | |
| SCHEMBL10928771 | 0.79 | KDM4E (0.72) | CNR2FAAHCNR1KDM4EALDH1A1 | |
| SCHEMBL31191005 | 0.79 | TSHR (1.00) | CNR2FAAHCNR1KDM4EALDH1A1 | |
| SCHEMBL30848679 | 0.78 | CNR2 (0.64) | CNR2FAAHMAPTHPGDTSHR | |
| SCHEMBL1150620 | 0.78 | KDM4E (0.70) | CNR2FAAHCNR1KDM4EALDH1A1 | |
| SCHEMBL3709144 | 0.78 | KDM4E (0.70) | CNR2FAAHCNR1KDM4EALDH1A1 | |
| SCHEMBL19747509 | 0.78 | KDM4E (0.70) | CNR2FAAHCNR1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1554649-A | Metabotropic glutamate receptor antagonists for treating central nervous system diseases | NPSҩ������˾ | 2004-12-15 | — | — | CN | claimed |
| US-20030013715-A1 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | NPS PHARMACEUTICALS, INC. | 2003-01-16 | — | — | US | claimed |
| CN-1285820-A | Metabotropic glutamate receptor antagonists for the treatment of central nervous system disorders | NPS PHARMA INC (US) | 2001-02-28 | — | — | CN | claimed |
| EP-2672971-A1 | METABOTROPIC GLUTAMATE RECEPTOR GROUP I ANTAGONISTS FOR TREATMENT OF ABNORMAL UNION OF TISSUE | Pharmalundensis AB (SE) | 2013-12-18 | — | — | EP | disclosed |
| WO-2012108831-A1 | METABOTROPIC GLUTAMATE RECEPTOR GROUP I ANTAGONISTS FOR TREATMENT OF ABNORMAL UNION OF TISSUE | REDECO CHEM AB (SE) | 2012-08-16 | — | — | WO | disclosed |
| US-7053104-B2 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | NPS PHARMACEUTICALS, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| CN-1554649-A | Metabotropic glutamate receptor antagonists for treating central nervous system diseases | NPSҩ������˾ | 2004-12-15 | — | — | CN | disclosed |
| CN-1158264-C | Metabotropic glutamate receptor antagonists for the treatment of central nervous system disorders | NPSҩ������˾ | 2004-07-21 | — | — | CN | disclosed |
| US-20030013715-A1 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | NPS PHARMACEUTICALS, INC. | 2003-01-16 | — | — | US | disclosed |
| US-6429207-B1 | QUINOXALINE DERIVATIVES EXHIBITING A HIGH DEGREE OF POTENCY AND SELECTIVITY FOR INDIVIDUAL METABOTROPIC GLUTAMATE RECEPTORS (MGLUR) | NPS PHARMACEUTICALS, INC. | 2002-08-06 | — | — | US | disclosed |
| CN-1285820-A | Metabotropic glutamate receptor antagonists for the treatment of central nervous system disorders | NPS PHARMA INC (US) | 2001-02-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013715-A1 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | GRM2, GRM1, GRM3 | CNR2 123/4885FAAH 445/4885MEN1 3259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.